Pharmaniaga is now a PN17 company

PETALING JAYA: Pharmaniaga Bhd has been classified as an affected listed issuer under Practice Note 17 (PN17) of the Main Market Listing Requirements of Bursa Malaysia.

In a filing with the stock exchange yesterday, the pharmaceutical company said it had triggered the PN17 criteria pursuant to its audited consolidated financial statements for the period ended Dec 31, 2022.

Save 30% OFF The Star Digital Access

Monthly Plan

RM 13.90/month

RM 9.73/month

Billed as RM 9.73 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 8.63/month

Billed as RM 103.60 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
Pharmaniaga , PN17 , regularisation plan

Next In Business News
Ancom Nylex inks RM76.8mil deal to dispose of 50% stake in new unit formed under restructuring
Ringgit extends gains to close higher as US rate cut expectations stay elevated
Gadang sells Selangor land for RM2.5mil
Stocks rise, dollar wilts as investors strap in for Fed rate cut
Bursa Malaysia ends lower as investors eye US data, BOJ decision
Quality Concrete subsidiary bags RM294.59mil contract for Mukah water supply system
Hartanah Kenyalang bags RM42.79mil construction contract in Sarawak
Bank Negara's international reserves at US$124.1bil as at Nov 28
Capital A expect to exit PN17 status by year-end
Felda proposes establishing national taskforce to develop oil palm carbon framework

Trending in Business

Others Also Read

Load more

Copyright © 1995- Star Media Group Berhad [197101000523 (10894-D)]

Best viewed on Chrome browsers.